This longitudinal study collected single milk samples from 163 mothers and multiple milk samples from 59 mothers in Jiangmen and Guangzhou, China at timepoints from post-partum day 3 until day 168 to analyze their HMO profiles.
In this newly published randomized clinical trial (RCT), bovine milk oligosaccharides (BMOs) was the only component which differed between the test formulas, hence, potentially the main driver for the observed effects on intestinal biomarkers and microbiota of the infant subjects.
Human milk oligosaccharides (HMOs) and bovine milk derived oligosaccharides (MOS) are bioactive components in infant nutrition that have been clinically demonstrated to have favorable gut microbiome modulating effects as well as beneficial effects on gastrointestinal related immunity.
In this prospective study, a total of 464 human milk samples were collected from 116 Chinese mothers from Beijing, Xuchang and Suzhou at four different time points. In total, 76.7% mothers were found to be Secretor and Lewis positive phenotype (Se+Le+).
Scientific advances have enabled a better understanding of some of the unique components in human milk, termed ‘bioactives’, which are thought to protect against infection and inflammation, and contribute to immune maturation and healthy microbial colonisation.
Diet, environment and microbiota in infancy are factors that can support gut barrier function and immune development. Studies show that nutrition interventions, particularly breastfeeding and human milk oligosaccharides, may influence the development of a normal microbiome.
Following a previous report demonstrating the safety and tolerance of an infant formula containing two major types of HMOs (2’-fucosyllactose and lacto-N-neotetraose), the authors further assessed the impact of HMO-supplementation on infant fecal community type as well as its relationship with re